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Chemokines play a critical role in inducing chemotaxis, extravasation, and activation of
leukocytes both in routine immunosurveillance and autoimmune diseases. Traditionally, to
disrupt chemokine function, strategies have focused on blockage of its interaction with the
receptor. Recently, it has been demonstrated that binding to glycosaminoglycans (GAGs) is
also required for the in vivo activity of many chemokines. Thus, interference with the
GAG-binding of chemokines may offer an alternative, valid, anti-inflammatory strategy.
However, the potential of using small polyanions to inhibit the interactions between chemo-
kines and cell surface GAGs has not been fully explored. In this study, a mass spectrometry
based filtration trapping assay was utilized to study the interactions between two CCR 2
ligands (MCP-1/CCL2 and MCP-3/CCL7) and a series of low molecular weight, polyanionic
molecules. Findings were confirmed by using a hydrophobic trapping assay. The results
indicated that Arixtra (fondaparinux sodium), sucrose octasulfate, and suramin were specific
binders of the chemokines, while cyclodextrin sulfate, although the most highly sulfated
molecule among the ones investigated, showed no binding. The binding stoichiometry of the
small molecule ligand was determined from the measured molecular weight of the noncova-
lent complex. Furthermore, the dissociation constant between MCP-3 and Arixtra was
determined by using electrospray ionization Fourier transform ion cyclotron resonance (ESI
FT-ICR) mass spectrometry, which compared favorably with the result of the isothermal
titration calorimetry (ITC) assay. The relative binding affinity of these ligands to MCP-3 was
also determined using a competitive filtration trapping assay. (J Am Soc Mass Spectrom 2006,
17, 524–535) © 2006 American Society for Mass SpectrometryChemokines are small (8–10 kDa), secreted pro-teins that have a critical role in a wide range ofbiological processes, including development,
lymphocyte homing, wound repair, and inflammation
[1, 2]. In addition to binding to, and signaling through,
the cell surface G-protein coupled receptors (GPCRs),
GAG binding is also one of the conserved properties of
chemokines and is critical for their in vivo functions
[3–5]. The specific interactions [6] of chemokines with
GAGs provide a mechanism for cell-surface retention
and presentation, especially in the presence of shear
forces [3]. The relevance of GAG binding in chemokine
function in vivo has been shown using a mouse perito-
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doi:10.1016/j.jasms.2005.12.008neal cell recruitment assay [7]. In contrast to the wild-
type chemokine that is effectively retained at the site of
injection, the non-GAG-binding chemokine mutant
moves rapidly out of the original tissue compartment.
Not surprisingly, this variant, unlike the wild-type
chemokine, was unable to recruit cells in vivo.
In another example, the critical role of the cell surface
GAG in chemokine-mediated cell recruitment has been
demonstrated in mice with inactivated NDST-1 (N-
acetyl glucosamine N-deacetylase-N-sulfotransferase-1)
[8]. This enzyme adds sulfate to heparan sulfate (HS)
chains during biosynthesis, and the mutation leads to a
significant attenuation in N-sulfation of the HS isolated
from endothelial cells. It was observed that chemokine
transcytosis and presentation at the lumenal surface in
the mutant mice were significantly reduced, resulting in
decreased neutrophil firm adhesion, migration, and, as
a result, infiltration.
To date, anti-inflammatory strategies have mainly
focused on inhibiting the chemokine-receptor interac-
tion using small molecules, soluble receptors (chemo-
kine binding proteins), and antibodies [4]. It has been
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GAG binding may also be an effective method for
targeting chemokine-mediated cell recruitment and in-
flammation [3, 7, 9]. Since there are significant redun-
dancies in the chemokine system (multiple chemokines
bind to the same receptor, and vice versa), a major
advantage of this strategy is that a molecule targeting
the conserved GAG binding site may circumvent the
complication of coordinated cell recruitment by multi-
ple chemokines [10].
Small, anionic molecules have been used to mod-
ulate the function of several heparin-binding pro-
teins. In one case, the binding of the dengue virus
envelop protein to a highly sulfated form of the cell
surface HS is one of the initial steps in infection. It
was shown that a small, polyanionic molecule,
suramin, could effectively compete off the dengue
virus envelope protein bound to heparin immobilized
on a microtiter plate, with a potency exceeding solu-
ble heparin. It was also observed that addition of
suramin to the culture completely prevented Vero
cells from infection by dengue virus [11, 12]. In
another example, Arixtra, a small heparin pentasac-
Scheme 1. Structures of the small, polyanioni
suramin, (d) cyclodextrin sulfate, and (e) fully scharide (Scheme 1a) was shown to bind specifically toantithrombin (AT) [13]. It has a critical 3-O -sulfate
[14], which is rare in the natural heparin sequences. It
is also modified with N-, 2-O-, and 6-O-sulfation. The
binding of Arixtra induces a conformational change
of AT, which significantly potentiates it as an inhib-
itor of the serine proteases, Factor Xa, and thrombin,
involved in blood clot formation [15]. This small
pentasaccharide has thus been used medically as an
anticoagulant drug. By blocking the interactions of
the chemokines with the cell surface GAGs, possibly
some small anionic molecules may function as inhib-
itors of cell recruitment and form the basis of novel
therapeutics for pathological immunoresponse.
Several instrumental methods have been established
for the characterization of protein/ligand noncovalent
complexes, including NMR, X-ray crystallography, sur-
face plasmon resonance (SPR), circular dichroism, light
scattering, isothermal titration calorimetry, size-exclu-
sion chromatography/native gel electrophoresis, and
fluorescence titration [16, 17]. The more recent charac-
terization of protein/ligand noncovalent complexes by
mass spectrometry has been aided by the development
of gentle ionization methods (electrospray ionization
lecules. (a) Arixtra, (b) sucrose octasulfate, (c)
ed heparin octasaccharide, Octa/12SO3.c moand matrix-assisted laser desorption/ionization). It has
526 YU ET AL. J Am Soc Mass Spectrom 2006, 17, 524–535been shown that specific noncovalent complexes are
observed under finely tuned instrument conditions
including, angle of the spraying needle, pressure of the
nebulizing/drying gas, capillary heating, and accelerat-
ing voltage at the nozzle-skimmer region [17–23]. Once
desolvated, the noncovalent complex ions can be ana-
lyzed for their molecular weight, binding stoichiometry
and relative/absolute binding affinity by mass spec-
trometry [21]. Indeed, mass spectrometry has been
applied to study enzyme-substrate, enzyme-inhibitor,
and even intact multimeric protein complexes [24 –26].
Compared with other characterization methods, mass
spectrometry has key advantages including sensitivity
and speed [17].
In this study, we investigate the interaction of two
chemokines, MCP-1/CCL2 and MCP-3/CCL7, with a
series of small, anionic molecules, with the goal of
identifying potential binders. This will facilitate the
design of therapeutics for pathological inflammation.
Two mass spectrometry based methods were used to
characterize these interactions. The first method was
a filtration trapping assay, which relies on the use of
salt washing with a molecular weight cut-off filter
and detection of the retained noncovalent complex.
This assay has been successfully used in a previous
study to screen for chemokine-binding heparin oligo-
saccharides and determine their binding stoichiome-
try using FT-ICR mass spectrometry [22]. The filtra-
tion trapping results for the small, anionic molecules
were confirmed by a hydrophobic trapping assay in
which the chemokine-GAG complex was adsorbed on
a hydrophobic column, and the specific ligands were
eluted using a high concentration salt wash. These
two methods were applied to study the binding of
small polyanions (Scheme 1), including Arixtra
(fondaparinux sodium), sucrose octasulfate (SOS),
suramin, and cyclodextrin sulfate, to the CCR2 li-
gands MCP-1 and MCP-3.
Experimental
Materials
All polymerases and restriction endonucleases were
purchased from New England Biolabs (Beverly, MA).
Enterokinase was expressed and purified as previously
described [27]. Heparinase I (EC 4.2.2.7) was purchased
from Calbiochem (La Jolla, CA). The human chemo-
kines MCP-1/CCL2 and MCP-3/CCL7 were expressed
and purified as previously described [22]. Suramin and
cyclodextrin sulfate were purchased from Sigma (St.
Louis, MO). Sucrose octasulfate was obtained from
Toronto Research Chemicals (Toronto, Canada). Hepa-
rin octasaccharide library was purchased from Dextra
Laboratories (Reading, UK). The other small anionic
molecules (Arixtra and the fully sulfated heparin oc-
tasaccharide) were prepared as described below.Filtration Trapping Assay
For the filtration trapping assay, 40 M the target
protein was mixed with 200 M (100 M for suramin)
of the ligand in 100 l of 100 mM NH4OAc (pH 6.8) at
room temperature. The solution was loaded onto a
centrifugal ultrafiltration unit with a molecular weight
cutoff of 10 kDa (Millipore, Billerica, MA) and subjected
to three times centrifugation (5000 rpm; 40 min; 4 °C),
each using 1 ml 200 mM NH4OAc (pH 6.8) as the
washing buffer. The retentate (50 l) was diluted by
addition of 1 volume of water and analyzed by ESI
FT-ICR mass spectrometry.
Hydrophobic Trapping, Elution, and Confirmation
of Bound Ligands
For the hydrophobic trapping assay, 40 M target
protein was incubated with 200 M the ligand in 100 l
of 100 mMNH4OAc solution (pH 6.8). The solution was
applied to an Oasis solid-phase extraction (SPE) car-
tridge (Waters, Milford, MA) that had been previously
conditioned using 1 ml of methanol and then 1 ml of
H2O. The solid-phase SPE cartridge was flushed three
times, each using 1 ml 200 mM NH4OAc solution (pH
6.8) and then eluted by 1 ml 760 mM NH4OAc (pH 6.8).
The eluate was desalted by extensive lyophilization or
by dialyzing against water using a dialyzer with a
molecular weight cutoff (MWCO) of 1 kDa (The Nest
Group, Southborough, MA).
Fourier Transform Ion Cyclotron (FT-ICR)
Mass Spectrometry
Mass spectra were acquired on a Bruker APEX II
7-tesla FT-ICR mass spectrometer (Bruker, Billerica,
MA), which was equipped with an Apollo (Bruker)
electrospray ion source. The noncovalent complex
ions were generated as previously described [21, 22].
Samples were infused into the mass spectrometer at 1
l/min using a syringe pump (Harvard Apparatus,
Holliston, MA). Nitrogen at 50 psi was used as the
nebulizing gas. The capillary exit voltage was ad-
justed to 140 V (positive mode) or 40 V (negative
mode) for ion desolvation. Ions were externally accu-
mulated in a radio frequency-only hexapole for 0.5 s
before transfer into the ICR cell for mass analysis.
Ions were trapped using gated trapping and detected
after chirp excitation. Between 8 and 100 broadband
time domain transients containing 512 k or 1024 k
data points were averaged before zerofill, Gaussian-
multiplication, and fast Fourier transform. The pa-
rameters of the ESI source, ion optics, and cell were
optimized for the best ion intensity. All the data were
acquired and processed using Xmass v 6.0.0 (Bruker,
Billerica, MA).
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with 12 Sulfates (Octa/12SO3)
Heparin octasaccharide modified with 12 sulfates
(Octa/12SO3, Scheme 1e) was isolated from the heparin
octasaccharide mixture by using strong anion-exchange
HPLC (SAX HPLC). Approximately 400 g of the
octasaccharide library was injected onto a CarboPac
PA1 column (Dionex, Sunnyvale, CA) and SAX HPLC
(Waters, Milford, MA) was performed at a flow rate of
1 ml/min using Solvent A (H2O, pH 3.5) and Solvent B
(3 M NaCl, pH 3.5). A typical gradient consisted of: (1)
1–11 min, 0% B, (2) 11–110 min, 0–100% B, and (3)
111–120 min, 0% B. Chromatograms were recorded by
monitoring the UV absorbance at 232 nm [28]. Fractions
corresponding to Octa/12 SO3 were collected, lyophi-
lized, and desalted.
Sample Preparation for Arixtra
Arixtra (fondaparinux sodium) was purchased from
GlaxoSmithKline (Research Triangle Park, NC). It was
subsequently desalted in preparation for mass spectro-
metric Kd measurements. One hundred microliters of
2.9 mM Arixtra solution was dialyzed against water for
3 to 4 days. The process of desalting was monitored by
ESI FT-ICR mass spectrometry. An enzyme-coupled UV
assay was used to determine the concentration of the
desalted Arixtra. Arixtra is susceptible to heparinase I
cleavage, which yields an unsaturated disaccharide
(containing the original reducing end) and a trisaccha-
ride (containing the original non-reducing end). The
enzymatically generated double-bond on the disaccha-
ride has a strong absorbance at 232 nm [28], and thus
the concentration of the disaccharide was determined
and correlated 1:1 to the original concentration of
Arixtra.
Digestion was performed in a 100 l solution of 20
mM Tris-HCl (pH 7.4), 1 mM CaCl2, 3 mU heparinase I,
and 2 l Arixtra at RT. The reaction was initiated by
addition of the enzyme and was continuously moni-
tored by UV absorption. The concentration of Arixtra
was calculated from the increase in the absorption at
232 nm, using a molar extinction coefficient of 3800
M1cm1 [29].
Dissociation Constant Determination by ESI
FT-ICR Mass Spectrometry
A titration experiment was employed for the MS disso-
ciation constant determination [30, 31]. The MCP-3
concentration was maintained at 10 M and Arixtra
was added at the following concentrations: 0.58, 1.16,
1.74, 2.32, 2.89, 4.34, 7.24, 14.5, 21.7, and 36.2 M. The
resulting solution was analyzed by ESI FT-ICR mass
spectrometry. Assuming a similar ionization efficiency
for MCP-3 and the MCP-3/Arixtra noncovalent com-
plex, the peak intensities directly correlated with the
solution concentrations and were used to calculate theaverage number of occupied binding sites on the pro-
tein, V, by using the following equation [32]:
V
Arixtrabound
proteinbound

 IMCP3/Arixtra
 IMCP3 IMCP3/Arixtra
(1)
Using the total protein concentration of 10 M, the
concentration of free Arixtra was calculated using the
following equation:
Arixtrafree Arixtratotal 10 *V (2)
The calculated V and [Arixtra]free from different con-
centration points of Arixtra analyzed were then fit
(GraFit version 4.0.12, Horley, Surrey, UK) into eq 3 [32]
to calculate the dissociation constant, Kd, and the num-
ber of binding sites, n.
V
n * Arixtrafree
Kd Arixtrafree
(3)
Dissociation Constant Determination by Isothermal
Titration Calorimetry (ITC)
For all ITC experiments, 1 mM Arixtra was titrated into
a 50 M solution of MCP-3 in 10 mM potassium
phosphate (pH 7.5), 100 mM NaCl in water. All exper-
iments were conducted at 25 °C. Titration of Arixtra
into MCP-3 was 1 injection of 1 l, followed by 52
injections of 5.999 l, with a 60 s initial delay and 250 s
between injections. Heats of injection were recorded
using the MCS-ITC (MicroCal, Northampton, MA) and
processed using Origin version 2.9 (OriginLab,
Northampton, MA), which reported the Kd, H, and n
(number of binding sites) of the chemokine-Arixtra
interaction.
Results and Discussion
We have demonstrated that ESI FT-ICR mass spectrom-
etry is a valuable tool to study protein-ligand interac-
tions [21–23, 33, 34]. In combination with a filtration
trapping assay, it was used for the screening of heparin
oligosaccharide ligands of chemokines [22]. In addition
to ligand identification, this label-free screening meth-
odology also allows for determination of the protein-
ligand binding stoichiometry [17]. As a complementary
method, a hydrophobic trapping assay was used to
confirm the results obtained from the filtration trapping
assay. We have extended the current MS methodologies
to study the binding between chemokines and a series
of small polyanions, including Arixtra, suramin, SOS,
and cyclodextrin sulfate (Scheme 1), with the goal of
identifying possible chemokine binding molecules that
may potentially function as competitive inhibitors of
chemokine-GAG interactions.
OS),
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Small Molecule Complexes
As shown in Figure 1a, wild type MCP-1 was initially
analyzed by spraying from a solution of 100 mM
NH4OAc. Under these conditions, MCP-1 exists primar-
ily as a monomer in equilibrium with a small amount of
dimer. This protein (40 M) was then incubated with
200 M Arixtra and the solution was loaded onto a
molecular weight cut-off filter and subjected to the
filtration trapping assay. Salt washing using 200 mM
NH4OAc has been demonstrated to effectively remove
the non-specific/low-affinity ligands and the molecules
subsequently detected as complexes with the protein
Figure 1. ESI mass spectra of (a) 5 M MCP-1
isotopic distribution of the ions at m/z 2166. The
isotopic distribution, and (b–e) filtration trappi
MCP-1. (b) Arixtra. [M  A], MCP-1 monomer
complex with Arixtra. (c) Sucrose octasulfate (Sare considered specific binders [22]. As shown in Figure1b, ions corresponding to noncovalent complexes be-
tween MCP-1 and Arixtra were clearly observed after
the 200 mM salt washing. One of the noncovalent
complex ions is consistent with a MCP-1 dimer in
complex with one Arixtra molecule, appearing at the
8 and 9 charge states. An ion of low abundance
corresponded to the monomer/Arixtra. Although the
concentration of Arixtra used was 5-fold that of the
chemokine, no monomer/2Arixtra or dimer/3Arixtra
complex was observed, indicating that non-specific
aggregation did not occur under these outlined condi-
tions.
Arixtra is a specific inhibitor of activated Factor X
(Xa) and has been used as an anticoagulant drug to treat
yed from 100 mM NH4OAc (pH 6.8). Inset, the
er ions (8) were clearly resolved as the lower
say of the small polyanionic molecules against
mplex with Arixtra; [D  A], MCP-1 dimer in
(d) suramin, and (e) cyclodextrin sulfate.spra
dim
ng as
in codeep vein thrombosis [35]. However, the interaction of
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plored. In one study, Arixtra was shown not to bind to
a CXC chemokine platelet factor 4 (PF4) [35]. The fact
that noncovalent complexes of MCP-1 and Arixtra
persisted after the salt wash indicates that Arixtra is a
specific ligand of MCP-1. This is the first reported
observation of the interaction between Arixtra and a
chemokine in vitro. We have shown previously that the
highly sulfated heparin octasaccharides bind to MCP-1
dimer, whereas no monomer complexed with the oc-
tasaccharide was observed, indicating a preferential
binding of the dimer to the oligosaccharides [22]. This is
encouraging as it has been shown that complexation of
GAG to some chemokines induces oligomerization [3].
However, in the case of Arixtra, both dimer/Arixtra
and minor monomer/Arixtra were observed (Figure
1b). This data suggests that a pentasaccharide is likely
not large enough to span the entire heparin-binding site
on the MCP-1 dimer, resulting in less preferential
binding to the MCP-1 dimer compared with a heparin
octasaccharide.
Sucrose octasulfate (SOS, Scheme 1b) has been
shown to bind to many heparin-binding proteins in-
cluding follistatin [36], fibroblast growth factor (FGF)
[37], and hepatocyte growth factor [38]. Noncovalent
complex ions were observed (Figure 1c) after a mixture
containing 40 M MCP-1 and 200 M SOS was sub-
jected to the filtration trapping assay. Again, one of the
noncovalent complexes observed indicated dimeric for-
mation of MCP-1 with one SOS molecule. Ions corre-
sponding to monomer/SOS and dimer/2SOS were also
observed, suggesting a somewhat different binding
stoichiometry from that of Arixtra. This interaction is
not totally unexpected because of the flexible sugar
backbone and its high degree of sulfation (8 sulfates/
molecule).
Although comparable in size with a heparin decasac-
charide, suramin contains a hydrophobic core that is
flanked by 6 sulfate groups (Scheme 1c) and is struc-
turally different from a heparin oligosaccharide [11]. It
has been shown that suramin binds to dengue virus
envelope protein, a heparin-binding protein, with an
identical affinity compared with heparin [12]. It is also
a ligand of aFGF and it has been suggested that the
binding site of suramin is located at or near the heparin-
binding site on aFGF [39].
Suramin was also investigated as a possible chemo-
kine binder. Our initial attempt to evaluate binding of
suramin to MCP-1 was unsuccessful because 200 M
suramin caused immediate precipitation of MCP-1.
When the concentration of suramin was lowered to 100
M and mixed with 40 M MCP-1, less aggregation
was observed. This solution was subjected to salt wash
and analyzed by FT-ICR mass spectrometry. As shown
in Figure 1d, the noncovalent complex between MCP-1
and suramin was observed in the mass spectrum.
However, in contrast to Arixtra, SOS, or the highly
sulfated heparin octasaccharides [22], binding to themonomer is clearly preferred and no MCP-1 dimer in
complex with suramin was observed.
Dissociation of multimeric protein complexes upon
suramin binding has been observed for several heparin-
binding proteins. For example, bFGF alone was found
to multimerize in solution. It also forms 2:1, 3:1, and 4:1
complexes with heparin decasaccharides [40]. How-
ever, the binding stoichiometry of bFGF and suramin
was found to be 1:1, indicating the dissociation of the
oligomers [39]. In another example, the oligomerization
state of human tumor necrosis factor  (TNF-) in the
presence of suramin was studied using size-exclusion
chromatography. TNF- exists as a trimer under phys-
iological conditions, and it was shown that suramin
promoted TNF- deoligomerization to monomers and
dimers [41]. The dissociation kinetics supports an allo-
steric model in which the binding of suramin induces a
conformation change of the trimeric TNF- to a state
that is more prone to dissociation. However, another
model in which suramin simply binds preferentially to
the monomer and/or dimer can not be ruled out. In the
case of MCP-1, the mass spectrometric binding data of
suramin is in accordance with either of these two
models. In one instance, the binding of suramin to
MCP-1 dimer might be transient, which results in the
rapid dissociation of the dimeric complex and the
observation of MCP-1 monomer/suramin. On the other
hand, it is also possible that the unique hydrophobic
moiety of suramin may interact with the MCP-1 mono-
mer at its dimer interface. This would contribute to the
preferential binding of suramin to MCP-1 monomer.
These two models cannot be differentiated by the
current experimental method, and further structural
studies will be needed to determine the exact binding
mechanism. However, since the dimer formation is
critical for the in vivo function of MCP-1 [42], the
binding of suramin to MCP-1 as well as disruption of
the dimer by the binding may be indicative of a
potential inhibitory effect on MCP-1.
Cyclodextrin sulfate (Scheme 1d) has the highest
degree of sulfation (average of 1415 sulfate per mol-
ecule) amongst the molecules investigated. However, it
showed no binding to MCP-1 after the salt wash using
200 mM NH4OAc (Figure 1e). Previously, Rusnati et al.
showed in a competition assay that cyclodextrin sulfate
was not able to displace heparin from immobilized HIV
TAT protein even at concentrations as high as 300 M
[43]. In agreement with its inability to affect the TAT/
heparin interaction [43, 44], cyclodextrin sulfate showed
no binding to MCP-1. These data suggest that a linear,
flexible backbone structure may be a critical determi-
nant for ligand binding to MCP-1.
Hydrophobic Trapping Analysis of the MCP-1/
Small Molecule Complexes
The results of the filtration trapping were confirmed
using the hydrophobic trapping assay. This method
oniu
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protein/protein complexes and small anionic mole-
cules. The target protein was incubated with the ligand
and then the solution was passed through a reverse
phase SPE cartridge. Proteins and protein/ligand com-
plexes are retained on the column and the non-specific
binders are removed by 200 mM salt washes. The
high-affinity binders are eluted by a salt wash using 760
mM NH4OAc.
This method was applied to test the binding of the
polysulfated molecules to chemokines. In three parallel
experiments, 40 MMCP-1 was incubated with Arixtra,
SOS, or cyclodextrin sulfate, each at a concentration of
200 M. Suramin was not tested because it is more
hydrophobic and binds strongly to the reverse-phase
SPE cartridge. Both Arixtra and sucrose octasulfate
were observed in the 760 mM salt elute fraction, clearly
indicating that they are specific binders of MCP-1
(Figure 2b). They were not observed in the high salt
elution fraction of the control experiment, in which only
the small molecule alone was loaded onto the column
(Figure 2c), indicating the absence of non-specific bind-
ing to the SPE cartridge. In contrast, cyclodextrin sulfate
did not bind to MCP-1. These data were in complete
accordance with the results of the filtration trapping
assay. This data also clearly indicates that binding is
Figure 2. Hydrophobic trapping assay of the
fractions were desalted and sprayed from a solve
small molecule standards, (b) the 760 mMNH4O
control experiments in which only the small mo
mM NH4OAc and eluted with 760 mM NH4O
sulfates. Additional smaller ions represent ammnot due to pure electrostatic interactions as cyclodex-trin sulfate was the most negatively charged molecule
chosen.
Filtration/Hydrophobic Trapping Analysis
of the Binding of Small Molecules to MCP-3
Both the filtration trapping and hydrophobic trapping
experiments were then repeated on the binding be-
tween MCP-3 and the small anionic molecules. The
spectrum of MCP-3 from a solution of 100 mMNH4OAc
(pH 6.8) is shown in Figure 3a. In contrast to MCP-1,
which exists in equilibrium between monomer and
dimer, only monomeric MCP-3 was observed.
Arixtra, suramin, and SOS were all observed to bind
to MCP-3, albeit MCP-3/SOS was observed at a very
low abundance (Figure 3). A binding stoichiometry of
1:1 was observed for all these ligands, indicating that
polyanionic molecules do not induce multimerization
of MCP-3. Cyclodextrin sulfate showed no binding to
MCP-3, suggesting that it is also not a ligand of this
chemokine.
The results of the filtration trapping assay were then
verified with Arixtra, SOS, or cyclodextrin sulfate and
MCP-3 by using the hydrophobic trapping assay. As
shown in Figure 4, Arixtra and SOS were observed in
the high salt elution fraction and not in the control
ll polyanionic molecules against MCP-1. The
50:50 MeOH:H2O with 10 mM NH4OH. (a) The
ution fraction, and (c) the elution fractions of the
e was loaded on the column, washed with 200
/14SO3, cyclodextrin sulfate modified with 14
m and sodium adducts.sma
nt of
Ac el
lecul
Ac. Cexperiment, indicating that they are specific ligands of
lfate.
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the eluate. The results of the hydrophobic trapping
assay were again in complete agreement with those of
the filtration trapping assay.
Kd Determination by ESI FT-ICR
Mass Spectrometry
Traditionally, the dissociation constant of a protein/
ligand noncovalent complex can be determined by
several methods, including surface plasmon resonance
(SPR), non-denaturing gel electrophoresis, and fluores-
cence titration [16, 17]. For example, the interactions
between chemokines and sulfated glycosphingolipids
(sulfatides) were studied using SPR [45]. It was ob-
served that various chemokines including MCP-1/
CCL2, IL-8/CXCL8, SDF-1/CXCL12, MIP-1/CCL3,
and MIP-1/CCL4 showed binding to sulfated glyco-
sphingolipids, but not to gangliosides, neutral glyco-
sphingolipids, or phospholipids. However, these meth-
ods have some limitations. SPR requires the
Figure 3. ESI mass spectra of (a) 5 M MCP-3
filtration trapping assay of the small polyanion
octasulfate, (d) suramin, and (e) cyclodextrin suimmobilization of either the ligand or the protein onsolid matrices, which may affect the binding properties
due to distortion of the binding site. The determination
of the binding stoichiometry by chromatographic meth-
ods depends on the elution or the mobility times, which
are sensitive to the shape and physical properties of the
protein. Thus, it is more affected by the calibrant
proteins [17].
Utilizing mass spectrometry, the protein and pro-
tein/ligand complex can be detected simultaneously.
Thus, ESI-MS can be used to determine the dissociation
constant for some protein-ligand complexes. One caveat
to this method is that the ratio of the protein and
protein/ligand complex must not change during the
transfer from solution into the gas-phase [21]. Possibly,
dissociation of the complexes or non-specific aggrega-
tion occurs during the ESI process. This results in an
inaccurate reflection of the solution concentrations of
the solution noncovalent complexes. For example, the
binding of rapamycin analogs to FKBP (FK506 binding
protein) has been studied using ESI-MS and ESI-
MS/MS experiments [46]. Since the binding is largely
yed from 100 mM NH4OAc (pH 6.8), and (b–e)
lecules against MCP-3. (b) Arixtra, (c) sucrosespra
ic modriven by hydrophobic effects, which diminish in the
oniu
532 YU ET AL. J Am Soc Mass Spectrom 2006, 17, 524–535gas-phase, the relative abundance of the complexes did
not correlate with the solution affinities. However, for
complexes composed of hydrogen bonding and electro-
static interactions, there are several examples in which
the solution binding affinities can be accurately re-
flected by the gas-phase data. This observation is
largely the result of the absence of “solvent screening”
in the gas-phase, which strengthens the ionic interac-
tions and prevents the complex from dissociating, thus
allowing the investigator to conduct titration experi-
ments. For example, the relative and absolute dissocia-
tion constants have been determined using ESI MS for
the NodH sulfotransferase [21] and Src SH2 domain
protein [31] systems, and the results compared favor-
ably with those of the solution characterization based
method.
Since the chemokine-GAG interaction is highly elec-
trostatic, we performed an MS determination of the
dissociation constant for the complex between MCP-3
and Arixtra. The dissociation constant of Arixtra for
MCP-3 was measured by maintaining the concentration
of MCP-3 at 10 M and titrating Arixtra from 0.58 to
36.2 M. The resulting mixture was analyzed directly
by ESI FT-ICR mass spectrometry. Only a 1:1 complex
formed between MCP-3 and Arixtra under these condi-
tions. Because the molecular weight of Arixtra is rela-
tively small compared with that of MCP-3 (16.8%), it is
Figure 4. Hydrophobic trapping assay of the
fractions were desalted and sprayed from a solve
small molecule standards, (b) the 760 mM NH4O
the control experiments in which only the small m
mM NH4OAc and eluted with 760 mM NH4O
sulfates. Additional smaller ions represent ammassumed that MCP-3 and MCP-3/Arixtra have similarionization efficiencies. Therefore, the measured ion in-
tensities in the mass spectra were used to calculate their
concentrations in solution. The average number of
occupied binding sites on the protein, V, was calculated
using eq 1. In this equation, IMCP-3 corresponded to the
ion intensities of free MCP-3 and IMCP-3/Arixtra corre-
sponded to those of the MCP-3/Arixtra complexes.
Since the total MCP-3 concentration is 10 M, the free
Arixtra concentration, [Arixtra]free, was calculated by
using eq 2. From this, V and [Arixtra]free were fit into eq
3 to derive the dissociation constant (Figure 5a). Based
on three replicate experiments, the dissociation constant
between MCP-3 and Arixtra was determined to be
7.71.1 M.
The number of binding sites, n (calculated from eq 3),
of MCP-3 is 0.23, whereas the binding stoichiometry
observed for the MCP-3/Arixtra noncovalent complex
is 1:1. This discrepancy indicates that saturation of the
protein was not reached in the Arixtra titration experi-
ment. One reason for the unsaturation was the suppres-
sion of ionization of the protein, and especially the
protein/Arixtra complex. A gradual decrease in the ion
intensities was observed when increasing concentra-
tions of Arixtra were titrated (data not shown). The
calculation of the number of binding sites is more
affected because it was calculated from the data points
at higher Arixtra concentrations. However, the data for
ll polyanionic molecules against MCP-3. The
50:50 MeOH:H2O with 10 mM NH4OH. (a) The
lution fractions, and (c) the elution fractions of
ule was loaded on the column, washed with 200
/14SO3, cyclodextrin sulfate modified with 14
m and sodium adducts.sma
nt of
Ac e
olec
Ac. Clower concentrations of Arixtra were less affected by
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tion constant could be obtained (see below for a com-
parison with the ITC data).
Dissociation Constant Determination by Isothermal
Titration Calorimetry (ITC)
Isothermal titration calorimetry is a well established
method for studying protein-ligand interactions. This
method allows determination of binding constants (Kd),
heats of binding (H), and the apparent number of
binding sites (n). The advantages of ITC include the
relative ease of analysis, the ability to determine ther-
modynamic parameters directly, and accurate determi-
nation of dissociation constants over a wide range of
affinities (millimolar–nanomolar). Unfortunately, ITC
requires large quantities of sample, and is somewhat
time intensive. In this study, ITC was an ideal solution
phase technique to use as a check on the mass spectro-
metric Kd determination. Isothermal titration calorime-
try requires no immobilization of chemokine or GAG
and can accurately measure the fairly weak chemokine-
GAG interactions. Based on three replicate experiments,
the dissociation constant of MCP-3 and Arixtra was
determined to be 3.5  1.2 M (Figure 5b and c).
Although two different buffer systems were used in the
MS and ITC experiments, the corresponding dissocia-
tion constant was in good agreement, validating the use
Figure 5. Dissociation constant determination
obtained from mass spectrometric analysis. Titr
experiments and one representative binding cur
titrated into a 10 MMCP-3 in 100 mM NH4OA
mass spectrometry. The average number of the o
Arixtra concentration, [Arixtra]free were fitted in
titration experiment and a representative bindin
titrated into a 50 M solution of MCP-3. The sol
mM NaCl in water.of electrospray FT-ICR in this particular case. Thenumber of binding sites was determined to be 0.9 
0.03, indicating MCP-3 forms a 1:1 complex with Arix-
tra. In addition, the ITC data also indicates that the
interaction between MCP-3 and Arixtra is an exother-
mal reaction with a H of 3172  86 cal/mol.
Determination of the Relative Order of Binding
Affinities
A competitive filtration trapping experiment was per-
formed in which the protein concentration was less than
the total ligand concentration [31]. Arixtra, SOS, and
suramin, each at a concentration of 100 M, were mixed
with 40 M MCP-3. One hundred micromolar Octa/
12SO3, a known heparin octasaccharide ligand [22] of
MCP-3, was also added. After three washings with 200
mM NH4OAc, the resulting solution was subjected to
ESI FT-ICR mass spectrometric analysis. Although the
same initial concentrations were used for these ligands,
different ion intensities were observed for the MCP-3
noncovalent complexes after washing (Figure 6). The
MCP-3 in complex with Octa/12SO3 is the most abun-
dant noncovalent complex ion, indicating Octa/12SO3
is the tightest binder. Less intense noncovalent complex
ions were also observed for suramin and Arixtra. Inter-
estingly, although suramin is not a heparin oligosaccha-
ride, the ion corresponding to its noncovalent complex
with MCP-3 is more abundant than that of Arixtra. This
Arixtra binding to MCP-3. (a) Binding curve
experiments were performed in three replicate
shown. Various concentrations of Arixtra were
resulting solution was analyzed by ESI FT-ICR
ied binding sites on the protein, V, and the free
3 to calculate the dissociation constant. (b) ITC
ve, (c). For ITC experiments, 1 mM Arixtra was
was 10 mM potassium phosphate at pH 7.5, 100for
ation
ve is
c. The
ccup
to eq
g cur
ventindicates that suramin has a reasonable binding affinity
say o
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that of Arixtra and SOS. No obvious SOS complex was
observed in the competitive binding assay. This is not
surprising, considering only very minor complexes
were observed when SOS alone was incubated with
MCP-3 and subjected to the salt wash. Thus, the com-
petitive binding assay clearly indicates that the relative
order of the binding affinities for the molecules studied
with MCP-3 is: Octa/12SO3  Suramin  Arixtra 
SOS.
Conclusions
The binding of a series of small, polyanionic molecules
to chemokines has been investigated using a mass
spectrometry based filtration trapping assay. Arixtra
(an anticoagulant drug) and SOS were observed to bind
to chemokines MCP-1 and MCP-3, while cyclodextrin
sulfate, although the most sulfated molecule, showed
no binding. This indicates that a flexible backbone
structure may be an important determinant for ligand
binding to chemokines. These results were confirmed
by an independent hydrophobic trapping assay. In
addition, suramin, a polysulfated binaphthyl urea, was
shown for the first time to bind to these two chemo-
kines. The dissociation constant of MCP-3 and Arixtra
was determined to be 7.7 M using ESI FT-ICR mass
spectrometry, which compared favorably with the
value determined using ITC experiments (3.5 M). This
indicates that mass spectrometry can be used as a
complementary method to determine the binding affin-
ities in such noncovalent complexes. Additionally, the
relative binding order of the ligands to MCP-3 was
determined as follows: Octa/12SO3  Suramin  Arix-
Figure 6. Competitive filtration trapping astra  SOS.Acknowledgments
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